Therapeutic inhibition of RAS in non-small cell lung cancer
Oncogenic KRAS mutations are the most common driver event in NSCLC, occurring in up to 30% of patients. Direct strategies to target KRAS (and other RAS isoforms) met with consistent failure until the discovery of covalent KRAS G12C inhibitors, leading to a first-in-class FDA accelerated approval for...
I tiakina i:
| Ngā kaituhi matua: | , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Frontiers Media S.A.
2026-06-01
|
| Rangatū: | Frontiers in Oncology |
| Ngā marau: | |
| Urunga tuihono: | https://www.frontiersin.org/articles/10.3389/fonc.2026.1817943/full |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|